The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Oral Alendronate Increases Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism
Abstract
The effect of biphosphonate therapy on bone mineral density (BMD) in patients with primary hyperparathyroidism (PHP) is unknown. Forty postmenopausal women (mean age, 70 yr) with PHP were randomized to receive alendronate 10 mg/d or placebo for 48 wk, followed by treatment withdrawal for 24 wk. The mean (+/-SD) changes in BMD at femoral neck (+4.17 +/- 6.01% vs. -0.25 +/- 3.3%; P = 0.011) and lumbar spine (+3.79 +/- 4.04% vs. 0.19 +/- 2.80%; P = 0.016) were significantly higher with alendronate at 48 wk. Serum calcium was reduced with alendronate but not placebo (-0.09 vs. +0.01 mmol/liter; P = 0.018). Serum bone-specific alkaline phosphatase activity was lower with alendronate from 12 wk onward and increased 24 wk after treatment withdrawal (21.1 +/- 12.8 to 7.3 +/- 4.9 IU/liter at 48 wk, and 15.0 +/- 14.8 IU/liter 24 wk after withdrawal; P = 0.002 for trend). Osteocalcin concentration decreased at 48 wk and increased 24 wk after alendronate withdrawal (P = 0.019 for trend of change over time) but not with placebo. Urinary N-telopeptide/creatinine ratio decreased with alendronate at 48 wk and increased 24 wk after treatment withdrawal (P = 0.008 for trend). N-telopeptide/creatinine ratio did not change with placebo. Alendronate improves BMD and reduces bone turnover markers in postmenopausal women with PHP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Cited by
Fraser, W. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60507-9 · Cited by 934
Khan, A. A., Hanley, D. A., Rizzoli, R., Bollerslev, J., Young, J. E. M., Rejnmark, L., Thakker, R., D’Amour, P., Paul, T., Van Uum, S., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-016-3716-2 · Cited by 544
Peacock, M., Bilezikian, J. P., Klassen, P. S., Guo, M. D., Turner, S. A., & Shoback, D. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0842 · Cited by 471
Ambrogini, E., Cetani, F., Cianferotti, L., Vignali, E., Banti, C., Viccica, G., Oppo, A., Miccoli, P., Berti, P., Bilezikian, J. P., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0219 · Cited by 404
Asymptomatic Primary Hyperparathyroidism
Bilezikian, J. P., & Silverberg, S. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmcp032200 · Cited by 377
Metadata
- Authors
- Chow, C. C., Chan, W. B., Li, J. K. Y., Chan, N. N., Chan, M. H. M., Ko, G. T. C., Lo, K. W., & Cockram, C. S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-02
- Volume
- 88
- Issue
- 2
- Pages
- 581-587
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2113108574
- Cited by
- 199
- References
- 1
- FWCI
- 10.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral Alendronate Increases Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism. https://app.cochat.ai/papers/10.1210/jc.2002-020890
- The paper
- Chow, C. C., Chan, W. B., Li, J. K. Y., Chan, N. N., Chan, M. H. M., Ko, G. T. C., Lo, K. W., & Cockram, C. S. (2003). Oral Alendronate Increases Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2002-020890
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.